PIKture-01: First-in-Human Study of the PI3KalphaH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and in Combination with Endocrine Therapy or HER2 Targeted Therapy in Participants with Advanced Breast Cancer
Details
Age
Adult
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Peter Kabos
Study ID
Protocol Number: 24-0016
More information available at ClinicalTrials.gov: NCT06239467
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers